Biodesix, Inc. (NASDAQ:BDSX) Director Buys $234,000.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack W. Schuler bought 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were acquired at an average price of $1.17 per share, with a total value of $234,000.00. Following the transaction, the director now directly owns 31,094,935 shares of the company’s stock, valued at $36,381,073.95. This represents a 0.65 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Biodesix Stock Up 0.8 %

Biodesix stock traded up $0.01 during trading on Thursday, reaching $1.20. 5,212,122 shares of the company were exchanged, compared to its average volume of 203,344. The company has a debt-to-equity ratio of 1.30, a quick ratio of 3.40 and a current ratio of 3.40. The stock’s 50 day simple moving average is $1.59 and its two-hundred day simple moving average is $1.61. Biodesix, Inc. has a 52-week low of $1.11 and a 52-week high of $2.21.

Biodesix (NASDAQ:BDSX) last announced its earnings results on Friday, November 1st. The company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The company had revenue of $18.15 million during the quarter, compared to analysts’ expectations of $18.45 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. During the same period last year, the business posted ($0.12) EPS. As a group, research analysts anticipate that Biodesix, Inc. will post -0.35 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BDSX has been the topic of several recent analyst reports. Scotiabank started coverage on shares of Biodesix in a research note on Monday, September 16th. They issued a “sector outperform” rating and a $3.00 target price on the stock. Craig Hallum began coverage on shares of Biodesix in a research report on Friday, July 26th. They set a “buy” rating and a $3.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Biodesix presently has a consensus rating of “Buy” and an average target price of $3.06.

Hedge Funds Weigh In On Biodesix

A number of hedge funds and other institutional investors have recently made changes to their positions in BDSX. AIGH Capital Management LLC lifted its holdings in Biodesix by 74.0% in the second quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company’s stock valued at $8,843,000 after acquiring an additional 2,458,727 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Biodesix during the second quarter valued at approximately $3,326,000. Farallon Capital Management LLC purchased a new position in shares of Biodesix during the 2nd quarter worth about $2,874,000. Geode Capital Management LLC boosted its holdings in shares of Biodesix by 50.7% in the 3rd quarter. Geode Capital Management LLC now owns 804,576 shares of the company’s stock valued at $1,433,000 after purchasing an additional 270,724 shares during the last quarter. Finally, Perkins Capital Management Inc. grew its position in Biodesix by 74.7% during the third quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company’s stock valued at $1,290,000 after acquiring an additional 310,000 shares during the period. Hedge funds and other institutional investors own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.